IP Library Granted Patent US 10,179,146
Granted Patent B1
US 10,179,146 · App. 15/800,841 · Granted Jan 15, 2019

Compositions and methods for mitigating drug resistant bacteria

Inventors: Shyam S. Mohapatra (Lutz, FL); Alya Limayem (Tampa, FL)
Assignee: University of South Florida
A61K31/722A61K9/1075A61K33/30A61K47/24C02F1/50C02F2303/04C02F2305/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,179,146
App. No.
15/800,841
Granted
Jan 15, 2019
Kind
B1
Abstract

A broad-based remediation mechanism against MRFs and alternative fecal indicators such as multidrug resistant Pseudomonas aeruginosa , including nanotechnology formulations and methodologies that may be used to develop novel mitigation strategies against certain drug resistant bacterial strains. The current invention relates to mitigation of drug resistant bacteria from nosocomial infections, for example in hospitals and in food animals, and to the identification and mitigation of lytic bacteria from algae biomass-fed wastewaters for algae cultivation. The invention uses hybrid nanomaterials comprising oligo-chitosan and zinc oxide formulated as nanoparticles and micelles. The inventors unexpectedly found unique properties of very small oligomers of chitosan that effectively mitigate MRF and alternative resistant strain-induced illnesses without compromising the balance of the beneficial flora in the physiological and ecological microenvironments. Also, the combination of chitosan with zinc oxide demonstrated synergistic and unexpected effects in remediation of important food-borne bacteria including the resistant types.

Claims (6)

1. A method of inhibiting Gram negative and Gram positive multi-drug resistant bacteria, comprising administering a combination of a therapeutically effective amount of chitosan oligomers and a therapeutically effective amount of zinc oxide nanoparticles, wherein the combination is selectively toxic against the multi-drug resistant bacteria.

2. A method as in claim 1 , wherein the pharmaceutically acceptable carrier is a nanomicelle composite.

3. A method as in claim 2 , wherein the nanomicelle composite includes the zinc oxide nanoparticles outlined by a hydrophobic shell formed of anionic lipid micelles with a coating of the chitosan.

4. A method as in claim 1 , wherein the molecular weight of the chitosan is about 3 kDa.

5. A method as in claim 1 , wherein the molecular weight of the combination of CZNPs with molecular weights of 3 KDa and 50 KDa; and wherein the combination used to treat a co-culture of Escherichia coli BAA-2471 and Enterococcus faecium has an average minimum inhibitor concentration of about 0.781 mg/mL to about 1.302 mg/mL.

6. A method as in claim 1 , wherein the multi-drug resistant bacteria include Escherichia coli and/or Enterococcus faecium.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 24, 2018
From: MOHAPATRA, SHYAM S.; LIMAYEM, ALYA
To: UNIVERSITY OF SOUTH FLORIDA
Reel/Frame 044715/0556 →
CONFIRMATORY LICENSE Recorded Jan 24, 2018
From: UNIVERSITY OF SOUTH FLORIDA
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 045137/0570 →
Continuity (2)
Continuation In Part 15298832 · Oct 20, 2016
Provisional Application 62243877 · Oct 20, 2015